Clinical trial
A Multicenter, Open-label, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam Individualized Dose From 1000 to 3000 mg/Day (Oral Tablets of 500 mg b.i.d.), Used as Monotherapy in Subjects (≥ 16 Years) Suffering From Epilepsy and Coming From the N01061 or the N01093 Trials.
NCT00150813 is registered in ClinicalTrials.gov with UCB Pharma SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open-label, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam Individualized Dose From 1000 to 3000 mg/Day (Oral Tablets of 500 mg b.i.d.), Used as Monotherapy in Subjects (≥ 16 Years) Suffering From Epilepsy and Coming From the N01061 or the N01093 Trials.
- Lead sponsor
- UCB Pharma SA
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 10, 2005
- Completion date
- May 29, 2007
- Enrollment
- 66 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.